CDKN2A and lymphoma: Similarly, in the phase 1 trial of ribociclib (another CDK4/6 inhibitor) in solid tumours and lymphoma, CDKN2A loss by next-generation sequencing was not associated with chance of remaining on drug ≥8 weeks, although CCND1 alterations were associated with response (our study had no patients with CCND1 amplifications).32